Effects of Almonds on Insulin Sensitivity in Prediabetes

Not Applicable

Completed

• Conditions: PreDiabetes
• Interventions: Other: 1.5 oz of whole, natural almonds; Other: Low-fat, high refined starches/sugars

• Registration Number: NCT03126981
• Lead Sponsor: Midwest Center for Metabolic and Cardiovascular Research

Brief Summary

The goal of this clinical trial is to evaluate the effects of consuming 1.5 oz almonds twice daily on insulin sensitivity and markers of cardiometabolic health in men and women with prediabetes.

Detailed Description

This is a randomized, controlled, two-period crossover study that includes two screening visits, and two 6-week test periods, separated by a 4-week washout. Subjects consume twice daily, 1.5 oz whole, natural almonds (Active Condition) or low-fat foods high in refined starches and added sugars, matched for energy content to the almonds (Control Condition). The assigned study products will be dispensed with instructions to consume 2 servings (Active Product) or 3 servings (Control Products) each day, starting on day 1. Subjects will be screened for prediabetes at the first screening visits. An intravenous glucose tolerance test (IVGTT) will be completed at baseline and the end of each treatment period. Fasting blood samples will be collected for lipid profile and high-sensitivity C-reactive protein (hs-CRP) measurements at all visits. Additionally, blood will be drawn for measurement of Apolipoprotein B and A1, lipoprotein particles and subfractions, Interleukin 6 (IL-6) and Uric acid at the beginning and the end of each test period. Assessments of vital signs, body weight, evaluation of inclusion and exclusion criteria, medication/supplement use, and adverse effects will be performed throughout the study. Compliance will be assessed through a daily log record, and return of unopened study product.

Study Timeline

• Study Start: 2017-04-20
• Study First Submitted: 2017-04-20
• Study First Submitted QC: 2017-04-20
• Study First Posted: 2017-04-25
• Primary Completion: 2018-09-26
• Study Completion: 2018-09-26
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-23
• Last Update Posted: 2019-07-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

1. BMI of 25.0-39.9 kg/m2
2. Prediabetic: fingerstick glycated hemoglobin 5.7-6.4% (inclusive), or fasting fingerstick capillary glucose of 100-125 mg/dL (inclusive), or 2-h post-prandial glucose of 140-199 mg/dL.
3. Fasting LDL-C level <200 mg/dL and fasting TG level <400 mg/dL.
4. Judged to be in general good health on the basis of medical history and screening laboratory tests.

Exclusion Criteria

1. Atherosclerotic cardiovascular disease including any of the following: clinical signs of atherosclerosis: peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease [symptomatic (e.g., transient ischemic attack or stroke of carotid origin) or >50% stenosis on angiography or ultrasound], history of myocardial infarction, angina, a revascularization procedure, or other forms of clinical atherosclerotic disease (e.g., renal artery disease).
2. History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type I or type II diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders.
3. Known allergy, sensitivity, or intolerance to any ingredients in the study foods.
4. Uncontrolled hypertension.
5. Recent history of cancer, except for non-melanoma skin cancer.
6. Recent change in body weight of ± 4.5 kg (9.9 lbs).
7. Recent use of any medications intended to alter the lipid profile (e.g. bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, and/or PCSK9 inhibitors, with the exception of the stable use of statins), weight-loss drugs or programs, systemic corticosteroid drugs, unstable use of any antihypertensive medication; medications known to influence CHO metabolism (e.g. adrenergic receptor blockers, diuretics, and/or hypoglycemic medications).
8. Recent use of food/supplements known to influence lipid metabolism (e.g. omega-3 fatty acid supplements (e.g., flaxseed, fish or algal oils) or fortified foods, sterol/stanol products; dietary supplements (red rice yeast supplements; garlic supplements; soy isoflavone supplements; niacin or its analogues at doses >400 mg/d, and irregular or inconsistent use of Metamucil® or viscous fiber-containing supplements.
9. Recent use of antibiotics.
10. Pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
11. Extreme dietary habits (e.g. very low CHO diet, vegan, etc.).
12. Current or recent history, or strong potential, for drug or alcohol abuse.
13. History of a diagnosed eating disorder. -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Whole, natural almonds	1.5 oz of whole, natural almonds	1.5 oz of whole, natural almonds
Low-fat, high refined starches/sugars	Low-fat, high refined starches/sugars	Low-fat foods,high in refined starches and added sugars

Primary Outcome Measures

Name	Time	Method
Insulin sensitivity index (SI)	43 days for each treatment period.	SI from a short (50-min) intravenous glucose tolerance test (IVGTT) at baseline(day 0) and end of two treatment periods (day 43 of both treatment periods)

Secondary Outcome Measures

Name	Time	Method
Fasting lipoprotein lipids	Up to 43 days for each treatment period.	Fasting blood samples will be collected for measurements of lipoprotein lipids including: Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non HDL-C, TC/HDL-C ratio and triglycerides (TG) at all visits.
Apolipoprotein (Apo) B and A1, Lipoprotein subfractions and particles	43 days for each treatment period	Fasting blood samples will be collected for measurements of Apo B1 and A1, and lipoprotein subfractions and particles at baseline (day 0) and end of the two treatment periods (day 43)
high-sensitivity C-reactive protein (hs-CRP)	Up to 43 days	Fasting blood samples will be collected for measurement of hs-CRP at all visits.
Serum Uric acid	43 days for each treatment period	Fasting blood samples will be collected to measure serum Uric acid levels at the beginning and end of each treatment periods.
Interleukin-6 (IL-6)	43 days for each treatment period	Fasting blood samples will be collected to measure serum IL-6 levels at baseline (day 0) and the end of the two treatment periods (day 43)

Trial Locations

Locations (2)

MB Clinical Research; 🇺🇸 Boca Raton, Florida, United States

Illinois Institute for Food Safety and Health (IFSH) at Illinois Instiute of Technology (IIT); 🇺🇸 Chicago, Illinois, United States